Senti Biosciences Inc Total Liabilities
Senti Biosciences Inc total liabilities. Based on the latest financial reports, Senti Biosciences Inc (SNTI) has total liabilities worth $44.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SNTI asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Senti Biosciences Inc (2019–2024)
Total liabilities of Senti Biosciences Inc from 2019 to 2024. This chart illustrates how Senti Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Senti Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Senti Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Braster S.A.
WAR:BRA
|
Poland | zł23.68 Million |
|
Citatah Tbk
JK:CTTH
|
Indonesia | Rp493.94 Billion |
|
Asia Pacific Fibers Tbk
JK:POLY
|
Indonesia | Rp1.11 Billion |
|
Trajano Iberia Socimi SA
MC:YTRA
|
Spain | €85.60 Million |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
USA | $142.94 Million |
|
GB Group plc
LSE:GBG
|
UK | GBX193.77 Million |
|
Exact Therapeutics AS
OL:EXTX
|
Norway | Nkr37.65 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Senti Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SNTI total assets.
Liquidity & Leverage Metrics
Senti Biosciences Inc Total Liabilities Ratios Explained
Senti Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Senti Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Senti Biosciences Inc (2019–2024)
The table below shows the annual total liabilities of Senti Biosciences Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $72.19 Million | +37.32% |
| 2023-12-31 | $52.57 Million | -1.79% |
| 2022-12-31 | $53.53 Million | +47.36% |
| 2021-12-31 | $36.33 Million | -66.07% |
| 2020-12-31 | $107.06 Million | +498.86% |
| 2019-12-31 | $17.88 Million | -- |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more